142 related articles for article (PubMed ID: 14745377)
1. Conference report - antiretroviral therapy update from the 9th European AIDS Conference.
Conway B
MedGenMed; 2003 Dec; 5(4):30. PubMed ID: 14745377
[No Abstract] [Full Text] [Related]
2. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
3. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
Moyle GJ; Gazzard BG
AIDS; 2002 May; 16(7):1086-7. PubMed ID: 11953482
[No Abstract] [Full Text] [Related]
4. Anti-HIV agents. Abacavir--as good as AZT?
TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
[No Abstract] [Full Text] [Related]
5. Triple nuke therapy--results after one year.
TreatmentUpdate; 2001; 12(10):3-4. PubMed ID: 11570063
[No Abstract] [Full Text] [Related]
6. Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
Feinberg J
AIDS Clin Care; 2006 Nov; 18(11):99. PubMed ID: 17183745
[No Abstract] [Full Text] [Related]
7. [First HIV triple therapy with one tablet].
Dtsch Med Wochenschr; 2000 Feb; 125(8):A22. PubMed ID: 10723466
[No Abstract] [Full Text] [Related]
8. AIDS drug in halted trial less effective as monotherapy.
AIDS Read; 2003 Apr; 13(4):159. PubMed ID: 12741364
[No Abstract] [Full Text] [Related]
9. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
[TBL] [Abstract][Full Text] [Related]
10. New formulations approved for children.
AIDS Patient Care STDS; 2008 Jan; 22(1):88. PubMed ID: 18453043
[No Abstract] [Full Text] [Related]
11. AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
Gallant JE
Hopkins HIV Rep; 2003 Jul; 15(4):1-2. PubMed ID: 14696559
[No Abstract] [Full Text] [Related]
12. AIDS foundation seeks withdrawal of approval for HIV drug combination.
Clarke B
Lancet Infect Dis; 2003 Oct; 3(10):604. PubMed ID: 14558502
[No Abstract] [Full Text] [Related]
13. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
Green H; Gibb DM; Walker AS; Pillay D; Butler K; Candeias F; Castelli-Gattinara G; Compagnucci A; Della Negra M; de Rossi A; Feiterna-Sperling C; Giaquinto C; Harper L; Levy J; Saidi Y; Wintergerst U;
AIDS; 2007 May; 21(8):947-55. PubMed ID: 17457088
[TBL] [Abstract][Full Text] [Related]
14. Where now for Trizivir? Role of the triple-NRTI pill post-ACTG 5095.
Moyle GJ
AIDS Read; 2003 May; 13(5):223-4, 227, 244. PubMed ID: 12800825
[No Abstract] [Full Text] [Related]
15. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Van Kasteren ME; Bravenboer B; Ten Kate RW; Groeneveld PH; van der Werf TS; Gisolf EH; Richter C
AIDS Patient Care STDS; 2010 Jun; 24(6):361-6. PubMed ID: 20515418
[TBL] [Abstract][Full Text] [Related]
16. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
[TBL] [Abstract][Full Text] [Related]
17. Trizivir on the market.
Kerr C
Trends Microbiol; 2001 Jan; 9(1):13. PubMed ID: 11166234
[No Abstract] [Full Text] [Related]
18. [Efficacy and safety of the substitution of zidovudine by nevirapine in treatments based on three nucleoside analogue reverse transcriptase inhibitors in HIV-1 infected patients].
Tasias M; Ruiz S; Deig E; Pedrol E
Enferm Infecc Microbiol Clin; 2011; 29(7):556-7. PubMed ID: 21565428
[No Abstract] [Full Text] [Related]
19. Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
Stürmer M; Dauer B; Moesch M; Haberl A; Mueller A; Locher L; Knecht G; Hanke N; Doerr HW; Staszewski S
Antivir Ther; 2007; 12(1):25-30. PubMed ID: 17503744
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S
Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]